Skip to main content
. 2011 Apr;49(4):1267–1273. doi: 10.1128/JCM.01679-10

Table 2.

Summary of selected patients in this studya

Group Patient Final classificationb No. of specimens positive by assay 1c No. of specimens positive by the GM ELISAd Risk factor(s)e Clinical sign(s)f AM at first classification or prophylaxisg
Possible/probable-IA patients detected by assay 1 M030 Probable 5h 1 a, t d P
V064 Probable 4h 2 n d, h P
M028 Possible 1 None a, t d P
M035 Possible 3h (A. fumigatus, A. flavus, A. terreus) None a, n d, h, c V
M036 Possible 1 None a, n, t d, h V
M037 Possible 2 None n d, h V
M039 Possible 1 None a, co, n, t d, ac
T095 Possible 1i 1 a, t Nonej P
V060 Possible 2 None n d
V062 Possible 2 None n d P
V063 Possible 1 None n d, h V
V069 Possible 1 (A. flavus) None n d
Possible/probable-IA patients not detected by assay 1 M033 Probable 0 1 a d E
M029 Possible 0 None a, n, t d, h P
M038 Possible 0 None a, n, t d, h
M040 Possible 0 None n d V
T090 Possible 0 None n d, h
T098 Possible 0 None a, t d P
T099 Possible 0 None n, a, t d
V049 Possible 0 None n, a d, h, c V
V065 Possible 0 None a, t d P
V070 Possible 0 None n d V
Unclassified patients detected by assay 1 T094 Not classified 1 None a, t None, AMk
V058 Not classified 1 None a, n, t None
V067 Not classified 1 None n None
M032 Not classified 1 None a, t None
M021 Not classified 1 None Nonel None
V042 Not classified 1 None n None, AMk
Unclassified patients detected by galactomannan ELISA T091 Not classified 0 1 a, t None
a

All patients that had either clinical signs of invasive aspergillosis (possible, probable, or proven IA according to EORTC/MSG criteria) or positive diagnostic results.

b

The final classification of the patient according to EORTC/MSG criteria as having proven, probable, or possible invasive aspergillosis.

c

Species detected are given in parentheses if they are not A. fumigatus.

d

A positive GM ELISA result is a microbiological criterion for IA per EORTC/MSG criteria.

e

Risk factors for invasive aspergillosis according to EORTC/MSG criteria: a, allogeneic stem cell transplantation; co, corticosteroid treatment; n, neutropenia; t, T-cell-suppressive therapy.

f

Clinical signs for invasive aspergillosis according to EORTC/MSG criteria (all referring to chest CT scans): ac, positive air crescent sign; c, cavitation; d, dense well circumscribed lesions; h, positive halo sign.

g

AM, antimycotic therapy was initiated at the time the patient was first classified as possibly or probably having IFI. V, voriconazole; P, posaconazole; E, echinocandin. All patients received fluconazole and/or topical polyene prophylaxis. Unclassified patients received antifungal prophylaxis at the time of the positive assay 1/galactomannan ELISA result.

h

These patients had consecutive positive assay 1 results.

i

Patient T095 also had one positive assay 2 result.

j

For patient T095, only nonspecific infiltrates were detected in a chest CT scan. Due to the multiplicity of positive biomarkers, we grouped this patient with the patients who possibly had IA despite T095's not formally fulfilling the EORTC/MSG criteria.

k

AM, antimycotic treatment with anti-Aspergillus efficacy was initiated in patients T094 (echinocandin) and V042 (voriconazole).

l

This patient was included due to an expected duration of neutropenia of >10 days; however, neutropenia then turned out to be <10 days.